

**Statement of Standalone Un-Audited Financial Results for the Quarter and Nine Months ended December 31, 2023**

(Rs. In Lakhs, unless otherwise stated)

Sr. No.	Particulars	Quarter ended			Nine Months ended		Year ended
		31/12/2023 (Unaudited)	30/09/2023 (Unaudited)	31/12/2022 (Unaudited)	31/12/2023 (Unaudited)	31/12/2022 (Unaudited)	31/03/2023 (Audited)
I	Revenue from Operations	1238.42	1309.61	1313.20	3913.94	3953.70	5265.53
II	Other Income	6.29	2.35	2.17	9.23	10.05	12.94
III	Total Revenue (I + II)	1244.71	1311.96	1315.37	3923.17	3973.75	5278.47
IV	Expenses :						
	(a) Cost of Material Consumed	515.61	437.95	479.59	1423.17	1542.50	2025.96
	(b) Purchase of Stock-in-Trade	-	-	-	-	-	-
	(c) Changes in Inventories of Finished Goods, Work-in-Progress & Stock-in-Trade	(130.45)	43.00	(24.55)	(63.88)	(66.29)	(19.25)
	(d) Employee Benefits Expenses	262.10	263.27	352.19	815.76	902.02	1118.74
	(e) Finance Cost	50.98	52.49	38.53	151.93	114.75	166.41
	(f) Depreciation and Amortisation Expenses	33.09	31.90	33.66	95.00	99.01	129.96
	(g) Other Expenses	472.43	451.08	399.61	1388.90	1265.06	1710.36
	Total Expenses (IV)	1203.76	1279.59	1279.03	3810.88	3857.05	5132.18
V	Profit / (Loss) before Exceptional Items and Tax (III - IV)	40.95	32.37	36.34	112.29	116.70	146.29
VI	Exceptional Items	-	-	-	-	-	-
VII	Profit / (Loss) Before Tax (V - VI)	40.95	32.37	36.34	112.29	116.70	146.29
VIII	Tax Expense :						
	(1) Current Tax	10.31	8.74	8.48	28.26	29.37	44.92
	(2) Deferred tax	-	-	-	-	-	1.17
	Total Tax Expenses	10.31	8.74	8.48	28.26	29.37	46.09
IX	Profit / (Loss) for the period from Continuing Operations (VII - VIII)	30.64	23.63	27.86	84.03	87.33	100.20
X	Profit / (Loss) from Discontinued Operations	-	-	-	-	-	-
XI	Tax expenses of Discontinued Operations	-	-	-	-	-	-
XII	Profit / (Loss) From Discontinuing Operations (after tax) (X-XI)	-	-	-	-	-	-
XIII	Profit / (Loss) for the period (IX+XII)	30.64	23.63	27.86	84.03	87.33	100.20
XIV	Other Comprehensive Income						
	A. (i) Items that will not be reclassified to profit or loss	-	-	-	-	-	-
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-	-
	B. (i) Items that will be reclassified to profit or loss	-	-	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	(11.61)
	Total Comprehensive Income for the period (XIII + XIV) (comprising Profit / (Loss) for the period after tax and Other Comprehensive Income after tax)	30.64	23.63	27.86	84.03	87.33	88.59
	Details of Equity share capital						
	Paid up Equity capital (Face Value of Rs.10/- each)	364.83	364.83	364.83	364.83	364.83	364.83
	Face value of Equity Share Capital	10.00	10.00	10.00	10.00	10.00	10.00
	Earnings Per Equity Share (for Continuing operation) :						
	(a) Basic	0.84	0.65	0.76	2.30	2.39	2.43
	(b) Diluted	0.84	0.65	0.76	2.30	2.39	2.43
	Earnings Per Equity Share :						
	Basic (Rs.)	0.84	0.65	0.76	2.30	2.39	2.43
	Diluted (Rs.)	0.84	0.65	0.76	2.30	2.39	2.43

**Notes**  
The above Statement of Standalone Unaudited Financial Results for the Quarter and Nine months ended December 31, 2023 ("Statement") is, as reviewed and recommended by the Audit Committee, considered and approved by the Board of Directors at its meeting held on February 14, 2024.  
The Statement is prepared in accordance with Indian Accounting Standards ("Ind AS") prescribed under Section 133 of the Companies Act, 2013 read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirement) Regulations, 2015 as amended and other accounting principles generally accepted in India.  
The Statement is subjected to "limited review" by the Statutory Auditors of the Company and they have expressed an unmodified audit opinion in Limited Review of the Standalone Unaudited Financial Results for the Quarter and Nine months ended December 31, 2023.  
The Management has identified the reportable segments in accordance with the requirements of IND AS-108 "Operating Segments", and decided that the Company has only one reportable business segment "Medical Devices".  
The previous period figures have been regrouped / rearranged wherever necessary to make it comparable with the current period.  
The Standalone Unaudited Financial Results for the Quarter and Nine months ended December 31, 2023 are available on the website of BSE Limited at www.bseindia.com and on Company's website at www.centenialindia.com.



for **CENTENIAL SURGICAL SUTURE LTD.**  
**VIJAY KALIDAS MAJREKAR**  
Digitally signed by VIJAY KALIDAS MAJREKAR  
Date: 2024.02.14 18:13:03 +05'30'  
Vijay MAJREKAR  
Managing Director & Chief Executive Officer  
DIN : 00804808

Place : Mumbai, Maharashtra  
Date : February 14, 2024